Loading…
Lobbying Spend
—
Filings
35
Firms Hired
2
Active Period
2017–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S 934/HR 2430, FDA Reauthorization Act of 2017; Issues related to the Orphan Drug Act.
Client expense: — · Firm income: $45,000
Matched citations: HR 2430
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
S 934/HR 2430, FDA Reauthorization Act of 2017; Issues related to the Orphan Drug Act.
Client expense: — · Firm income: $45,000
Matched citations: S 934
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Issues related to the Orphan Drug Act, FDA user fee agreements and S. 934.
Client expense: — · Firm income: $45,000
Matched citations: S. 934
Source: Senate LDA